FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Massachusetts General Hospital
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Massachusetts General Hospital (8)
2024
-
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies
Archives of Pathology and Laboratory Medicine, Vol. 148, Núm. 7, pp. 757-774
2022
-
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma
Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 793-805
-
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354
2021
-
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
Journal of Thoracic Oncology, Vol. 16, Núm. 4, pp. 686-696
2020
-
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Journal of Thoracic Oncology, Vol. 15, Núm. 4, pp. 499-519
-
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Journal of Thoracic Oncology, Vol. 15, Núm. 9, pp. 1409-1424
2019
-
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 377-407
-
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
Annals of Oncology, Vol. 30, Núm. 9, pp. 1417-1427